top of page

ANAVEX New Website - Untitled Page.png

Search

Investigating the Potential Neurorestorative Effects of a Clinical Sigma-1 Receptor Agonist

ANAVEX® Life Sciences Corp.
Nov 11, 2016
1 min read

World Parkinson Congress 2016, Portland, OR

V. Francardo, F. Bez, J. Sprouse, C. Missling, M.A. Cenci

View Poster

Recent Posts

Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East

Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

bottom of page